Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biogen Idec

Biogen Idec building

Biogen discontinues clinical development of anti-tau antibody for Alzheimer’s disease

The drug failed to meet the primary efficacy endpoint in a phase 2 study

Biogen Idec building

Biogen to begin shipping newly approved Alzheimer’s treatment in two weeks

Just days after the drug was approved by the FDA advisory panel, two of its members have resigned

- PMLiVE

FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision

FDA is requiring Biogen to conduct a new randomised, controlled clinical trial to verify the drug’s clinical benefit for Alzheimer’s patients

- PMLiVE

Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s

Patients from a small phase 2a study saw their ADAS-Cog11 scores improve by 4.4 points

- PMLiVE

Alzheimer’s disease: the search for a cure

To ensure the successful discovery and development of new dementia therapies, key gaps in the field need to be addressed

Roche Basel Switzerland

Roche reports strong diagnostics sales in Q1 as demand for COVID-19 tests continues

Company continues to report a significant impact of biosimilar competition on established brands

- PMLiVE

Lilly to expand donanemab study in a bid for approval in Alzheimer’s disease

Lilly revealed expanded findings from phase 2 TRAILBLAZER-ALZ study this week

- PMLiVE

Researchers use AI to identify drugs that could be repurposed for Alzheimer’s

Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing

- PMLiVE

ICER extends evaluation of Biogen’s aducanumab after FDA delay

FDA delayed its decision on potential Alzheimer's therapy to 7 June

- PMLiVE

Novartis hit by ‘COVID-19-related lockdowns’ in Q4

Sales grew in the quarter but profits fell short of forecasts

- PMLiVE

Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes

Drug demonstrated a 'significant' slowing of cognitive decline

- PMLiVE

Novo Nordisk launches late-stage study in Alzheimer’s disease

Study will evaluate oral semaglutide in neurodegenerative disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links